WOMEN AND INFANTS TRANSMISSION STUDY--CHICAGO

WITS是对围产期艾滋病毒感染的开创性研究。它有一个范围广泛的 从一大批艾滋病毒感染者那里寻求深入信息的议程 妇女和她们的婴儿。目前的芝加哥WITS-I小组包括 伊利诺伊大学芝加哥分校，西北大学，儿童 纪念医院和库克县医院。芝加哥的队员们已经 对这项研究的科学合作议程做出了贡献， 制定国家执行这项研究的程序，如 以及在当地，并在特定协议和 传播成果。他们还获得了其他赠款支持 基础科学和流行病学研究和临床试验 与智者互动，扩大其范围。 到1992年12月，芝加哥的网站招募了116名感染艾滋病毒的孕妇 妇女、39名未怀孕的艾滋病毒感染妇女和79名婴儿。在过去的几年里 年份西北大学(包括儿童纪念医院)和 库克县医院开始招募参与者。在过去的6年中 几个月来，芝加哥的平均入学人数为每月5.2人，即62人 每年。芝加哥大学还提议将芝加哥大学增加为 WITS-II的额外站点。因此，保守估计 WITS-II第一年的招生人数将为75人，不包括 考虑到血清阳性率的增加。HIV感染的血清阳性率 伊利诺伊州匿名新生儿怀孕调查 1992年比上年增长52%。尽管芝加哥一直是 中等血清阳性区，这些数字表明 围产期艾滋病毒感染的流行。芝加哥智囊团的网站将在 一个监测疫情变化动态的独特职位。 芝加哥集团将继续贡献高质量的数据和创新 想法。94%的考察访问是按时完成的，91%的参与者 最初登记的学生继续参加研究，超过92%的 病史、体格检查和人口统计表格齐全或 很快就会有比赛了。超过90%的指定实验室研究 获得了91%的HIV培养和92%的淋巴细胞 表型研究。为了提高WITS-II的科学价值， 芝加哥团队提出了几个发展研究主题，以解决 智慧的中心目标。这些检查包括检测人类白细胞抗原、TH1/TH2 淋巴细胞“平衡”、细胞凋亡和合胞体形成病毒分离株 垂直传播或疾病快速发展的风险。其他 研究将通过原位聚合酶链式反应检测胎儿组织中的病毒并进行比较 母体-胎儿病毒包膜序列更好地确定疾病分期 感染时发生的妊娠。此外，该小组还建议 研究在孕妇身上进行疫苗研究的可行性。 这些发展研究主题与具体目标直接相关。 智慧，并利用已有的数据和样本或 可以很容易地并入WITS-II协议。 拟议的计划将继续芝加哥小组在WITS-II中的工作。 创新的特点、工作质量和效率 小组将提高WITS-II的整体科学生产力。

WITS is a seminal study of perinatal HIV infection. It has a wide-ranging agenda seeking in-depth information from a large cohort of HIV infected women and their infants. The current Chicago WITS-I group includes the University of Illinois at Chicago, Northwestern University, Children's Memorial Hospital and Cook county Hospital. Chicago team members have contributed to the scientific collaborative agenda of the study, the development of procedures for the execution of the study nationally as well as locally, and have provided leadership in specific protocols and dissemination of results. They have also received other grant support for basic scientific and epidemiologic studies and clinical trials that interact with WITS and extends its scope. Through December 1992, the Chicago site enrolled 116 pregnant HIV infected women, 39 non-pregnant HIV infected women, and 79 infants. During the last year Northwestern University (including Children's Memorial Hospital) and Cook County Hospital started enrolling participants. For the last 6 months, the average Chicago enrollment has averaged 5.2 per month or 62 per year. Chicago also proposes adding University of Chicago as an additional site for WITS-II. Therefore, it is conservatively estimated that enrollment for year 1 of WITS-II will be 75, without taking into account an increase in seroprevalence. The seroprevalence of HIV infection in pregnancy by anonymous newborn survey in the State of Illinois increased 52% 1992 over the preceding year. Although Chicago has been a moderate seroprevalence area, these figures suggest an important surge in the epidemic of perinatal HIV infection. The Chicago WITS site will be in a unique position of monitoring the changing dynamics of the epidemic. The Chicago group will continue to contribute quality data and innovative ideas. 94% of study visits were completed on time, 91% of participants originally enrolled have continued in the study, and greater than 92% of historical, physical examination and demographic forms are complete or will be competed shortly. More than 90% of indicated laboratory studies were obtained, including 91% of HIV cultures and 92% of lymphocyte phenotyping studies. To enhance the scientific value of WITS-II, the Chicago team proposes several developmental research topics that address central aims of WITS. These include examination of HLA antigens, TH1/TH2 lymphocyte "balance", apoptosis and syncytium forming viral isolates on the risk of vertical transmission or rapid disease progression. Other studies will examine virus in fetal tissue by in situ PcR and compare maternal-fetal viral envelope sequences to better define the stage of pregnancy at which infection occurs. In addition, the group proposes examining the feasibility of doing vaccine studies in pregnant women. These developmental research topics relate directly to the specific aims of WITS and make use of data and samples already available or samples that can be readily incorporated into the WITS-II protocol. The proposed plan will continue the work of the Chicago team in WITS-II. The innovative characteristics, quality of work and efficiency of the group will enhance the overall scientific productivity of WITS-II.